Company Legal Name
Latest Valuation
Founded Year
Headquarter
Innorna is a biotechnology company developing mRNA vaccines and therapeutic treatments through its proprietary lipid nanoparticle delivery platform. Based in Sha Tin, the company focuses on advancing mRNA technology for targeted medical applications, leveraging specialized delivery mechanisms to enhance therapeutic efficacy. Innorna's approach centers on optimizing the stability and delivery of mRNA-based treatments, addressing key challenges in the rapidly evolving mRNA therapeutics sector. While specific funding details and valuation metrics remain undisclosed, the company operates within the competitive landscape of next-generation vaccine and therapy development. Innorna continues to advance its proprietary platform technology and expand its mRNA-based therapeutic pipeline.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.





